Phenylalanine News and Research

RSS

BioMarin receives notice of allowance for Kuvan patent

BioMarin Pharmaceutical Inc. has announced that it has received a notice from the United States Patent Office reporting allowance of claims covering once daily dosing methods for Kuvan (sapropterin dihydrochloride) in the treatment of phenylketonuria (PKU).

30 Mar 2009

Novel stimulation method sparks hope for Parkinson's disease sufferers

A novel stimulation method, the first potential therapy to target the spinal cord instead of the brain, may offer an effective and less invasive approach for Parkinson's disease treatment, according to pre-clinical data published in the journal Science by researchers at Duke University Medical Center.

20 Mar 2009

New drug shows promise for phenylketonuria

PKU is described by scientists as an autosomal recessive genetic disease that is characterized by a deficiency in an enzyme called phenylalanine hydroxylase (PAH).

15 Jan 2009

Merck Serono's Kuvan receives European marketing authorization

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that the European Commission has granted marketing authorization for Kuvan(R) for the treatment of hyperphenylalaninemia (HPA) in phenylketonuria (PKU) or BH4 deficient patients.

10 Dec 2008

An improved gene therapy agent from University of Florida

Replacing one amino acid on the surface of a virus that shepherds corrective genes into cells could be the breakthrough scientists have needed to make gene therapy a more viable option for treating genetic diseases such as hemophilia, University of Florida researchers say.

19 May 2008

Drug therapy for phenylketonuria reverses heart damage

A pricy drug used to treat a rare but well-known genetic disorder may hold wider promise as a treatment for millions of Americans with potentially lethal enlarged hearts, due mainly to high blood pressure, a study from Johns Hopkins shows.

13 May 2008

New method to determine the “selective signature” of a gene

Scientists at MIT have come up with a mathematical approach for analyzing a protein simultaneously in a set of ecologically distinct species to identify occurrences of natural selection in an organism's evolution.

19 Mar 2008

New phenylketonuria (PKU) treatment offered at Hayward Genetics Center

No pizza. No ice cream. No hotdogs and definitely no hamburgers. What sounds like a list of banned food for someone trying to lose weight is actually a way of life for children with a rare metabolic disorder, phenylketonuria (PKU), which prevents digestion of an essential amino acid found in most meats, eggs, dairy products, nuts and breads.

10 Jan 2008

BioMarin Pharmaceutical announces FDA approval for Kuvan

BioMarin Pharmaceutical Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Kuvan(TM) (sapropterin dihydrochloride) Tablets, the first specific drug therapy approved for the treatment of phenylketonuria (PKU).

14 Dec 2007

BioMarin files investigational NDA for PEG-PAL for the treatment of phenylketonuria

BioMarin Pharmaceutical Inc. has announced that it has filed an investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) for PEG-PAL (Poly Ethylene Glycol-Phenylalanine Ammonia Lyase), formerly known as Phenylase, for the treatment of phenylketonuria (PKU).

27 Nov 2007

Benefits and risks of breastfeeding

Extensive medical research shows that mothers' milk satisfies babies' nutritional needs far better than any manufactured infant formula.

17 Sep 2007

Scientists convert the sequence of proteins into music

UCLA molecular biologists have turned protein sequences into original compositions of classical music.

17 May 2007

New type of buckyball

Scientists at Rice University and Baylor College of Medicine have developed a new type of buckyball nanoparticle that acts as a passkey, allowing peptide-based drugs to enter cancer cells.

29 Jan 2007

FDA affirms safety of Aspartame

The Calorie Control Council has stated that a rat study conducted by Italy's Ramazzini Institute is totally contradictory to the extensive scientific research and regulatory reviews conducted on aspartame. The U.S. Food & Drug Administration (FDA) has said they are not recommending any changes in the use of aspartame.

13 Feb 2006

Technique for inserting genes into specific sites on the genome in liver cells

The genes are inserted into non-coding regions of the genome so there is no danger of interfering with the functioning of other genes. Once inserted, the gene remains a permanent part of the cell's genome.

10 Oct 2005

Key step in the entry of anthrax toxin into human cells

The work, which grew out of an ongoing effort to produce a better anthrax therapeutic, shows that the protective antigen component of the bacterial toxin plays an active role in transferring the other two components of the toxin through the cell membrane.

28 Jul 2005

Fickle enzyme helps protect, but also can promote heart failure

Enzymes that make the gas nitric oxide (NO) not only protect the heart from damage due to high blood pressure or a heart attack, but also promote heart failure through overgrowth and enlargement of the muscle tissue, say animal researchers at Johns Hopkins.

26 Apr 2005

Breakdown in brain cell communication may contribute to the most common biochemical cause of mental retardation

The process is akin to a baseball game gone bad. Imagine if a pitcher were joined by six players simultaneously winding up on the mound. Crouched behind home plate, the single catcher would soon be overwhelmed. Even if the coach sent in teammates to catch the extra balls, confusion would reign on the field.

12 Apr 2005

First home-testing device for phenylketonuria (PKU) patients

Home-testing kits have made it easier for diabetics and hypertension patients to track their conditions, but such self-monitoring hasn’t been possible for people with phenylketonuria (PKU).

1 Nov 2004